:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/shawmedia/3JWVWHE7UPU2RJMTOJOM6YSFHM.jpg)
Oxford Technology 2 VCT (GB:OXH) recently reported an increase in net asset value (NAV) per share, thanks to successful clinical trial results from Arecor Therapeutics. However, the share price of Arecor declined unexpectedly due to fundraising needs. Meanwhile, Scancell Holdings experienced a slight drop in share price despite signing an exclusivity agreement with a major biotech firm.
In response to operational costs, Oxford Technology 2 VCT announced plans to liquidate a portion of its portfolio. Despite this, no dividends were issued and no shares were traded during the quarter. Investors can find more detailed insights on GB:OXH stock by visiting TipRanks’ Stock Analysis page.
Overall, Oxford Technology 2 VCT has faced fluctuations in its portfolio performance due to various industry factors. As such, investors should closely monitor these developments and seek professional advice when making investment decisions related to GB:OXH stock.
